Low grade fibromyxoid sarcoma

Summary

Low grade fibromyxoid sarcoma (MONDO:0006272) is a cancer and 3 clinical trials. Top therapeutic interventions include pazopanib, ifosfamide, and seclidemstat. A subtype of fibrosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	low grade fibromyxoid sarcoma
Mondo ID	MONDO:0006272
NCIT	C45202
SNOMED CT	404088004
UMLS	C1275282
MedGen	224814
GARD	0024355
Is cancer (heuristic)	yes

Also known as: low grade fibromyxoid sarcoma · low-grade fibromyxoid sarcoma

Data availability: 1 cell line.

Disease family

This is a subtype of fibrosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › fibroblastic neoplasm › fibrosarcoma › low grade fibromyxoid sarcoma

Related subtypes (10): bone fibrosarcoma, conventional fibrosarcoma, pediatric fibrosarcoma, kidney fibrosarcoma, breast fibrosarcoma, heart fibrosarcoma, central nervous system fibrosarcoma, small intestinal fibrosarcoma, liver fibrosarcoma, dermatofibrosarcoma protuberans

Subtypes (1): low grade fibromyxoid sarcoma with giant collagen rosettes

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02180867	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT03967834	Not specified	RECRUITING	Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PAZOPANIB	4	3
IFOSFAMIDE	4	1
SECLIDEMSTAT	2	1
CHEMBL4068768	0	1
CHEMBL4171277	0	1